AstraZeneca

Source: www.moreover.com --- 26 days ago
Drugs firm AstraZeneca and partner Targacept Inc announced disappointed results from the Phase IIb clinical trial of AZD3480, which proved 'inconclusive' for the treatment of Alzheimer's. In the 12-week placebo-controlled study, neither AZD3480 nor ...

Source: www.marketwatch.com --- 20 days ago
Most drug stocks are marginally lower, but shares of AstraZeneca PLC climb in the wake of a series of stock repurchases. ...

Source: www.prweb.com --- 9 days ago
Dynavax Technologies, Inc. (NASDAQ:DVAX) today announced receipt of a $4.5 million milestone payment from its partner AstraZeneca AB for the nomination of candidate drug AZD1419 for the treatment of asthma and chronic obstructive pulmonary disease (COPD). As part of this potential $136 million development and commercialization collaboration, AstraZeneca and Dynavax have initiated Investigational New Drug (IND) enabling studies with AZD1419 and plan to begin phase 1 clinical development in 2009. (PRWeb Sep 22, 2008) Read the full story at http://www.prweb.com/releases/dynavax_technologies/clinical_development/prweb1368074.htm ...

Source: www.marketwire.com --- 3 days ago
ST. LOUIS, MO (MARKET WIRE) Tripos International, a leading provider of drug discovery informatics products and services, today announced a collaboration agreement with AstraZeneca to develop a new drug discovery workflow solution. ...

Source: www.businesswire.com --- 2 days ago
CHICAGO--(BUSINESS WIRE)--Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting ...

Source: www.moreover.com --- 31 days ago
MarketWatch Sep 11 2008 9:08AM GMT ...

Source: www.drugs.com --- 1 day ago
Ramped Up Marketing Efforts and FDA Activity Drive Growth at Top Brand.com Sites RESTON, Va., October 09, 2008 /PRNewswire-FirstCall/ -- comScore, Inc. , a leader in measuring the digital world, today released a study of the top pharmaceutical brand... ...

Source: www.moreover.com --- 2 days ago
Business Wire via MSN Money Oct 10 2008 11:23AM GMT ...

Source: www.drugs.com --- 1 day ago
LONDON, Oct. 10, 2008--AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved once-daily SEROQUEL XR (quetiapine fumarate) Extended-Release Tablets for the acute treatment of the depressive episodes associated with... ...

Source: industry.bnet.com --- 13 hours ago
AstraZeneca's Nexium is most-visited drug website, Genentech voted best place to work, fewer DDMAC warning letters over time, GSK execs talk research. ...

Source: industry.bnet.com --- 13 hours ago
Teva, the generic maker, is suing AstraZeneca, the holder of the original Crestor patent, claiming that AZ is somehow infringing on rights Teva acquired to the drug back in March 2007. The Crestor patent isn’t supposed to expire until 2016 — well beyond the industry’s looming patent cliff, which is why certain analysts think AZ is [...] ...

Source: www.medicalnewstoday.com --- 23 days ago
Seroquel XL (quetiapine prolonged release) a new, once daily formulation for schizophrenia and manic episodes associated with bipolar disorder, has today become available in the UK.[1] The new formulation was developed to address the needs of patients who require effective control of symptoms in a once daily rather than twice daily tablet. ...

Source: www.moreover.com --- 23 days ago
EPharmaceuticals Sep 19 2008 3:37AM GMT ...

Source: www.medicalnewstoday.com --- 24 days ago
AstraZeneca (NYSE: AZN) and Targacept, Inc. (NASDAQ: TRGT) announced that results from the Phase 2b clinical trial of AZD3480 (TC-1734) conducted by AstraZeneca in mild to moderate Alzheimer's disease were inconclusive. In the 12-week placebo-controlled study, known as the Sirocco trial, neither the active comparator donepezil nor AZD3480 met the trial's criteria for statistical significance on the primary outcome measure, ADAS-Cog1. ...

Source: www.moreover.com --- 24 days ago
Pharmaceutical Business Review Sep 17 2008 7:51AM GMT ...

Source: clientportal.ibb.ubs.com --- 32 days ago
This document is related to the following: Regions Europe Including UK United Kingdom Global UBSW EMEA Sectors European Pharmaceuticals British Pharmaceuticals Global Pharmaceuticals European Healthcare British Healthcare Global Healthcare Companies AZN.L AstraZeneca GSK.L GlaxoSmithKline Subjects Morning Note ...

Source: www.jobster.com --- 27 days ago
Responsibilities The Pharmaceutical Sales Specialist (PSS) will 1) ensure that sales forecasts are met (or exceeded) within budget for the therapeutic areas at a territory level 2) work with the District Sales Manager (DSM) and Regional Account Direc ...

Source: www.jobster.com --- 23 days ago
ResponsibilitiesThe Pharmaceutical Sales Specialist (PSS) will1) ensure that sales forecasts are met (or exceeded) within budget for the therapeutic areas at a territory level2) work with the District Sales Manager (DSM) and Regional Account Director ...

Source: www.24-7pressrelease.com --- 2 hours ago
XTractor - The first of its kind scientific literature alert service launched in July '08 has built a user base of over 900 users form more than 150 premier organizations. ...

Source: www.stockworld.de --- 30 days ago
London (aktiencheck.de AG) - Der britische Pharmakonzern AstraZeneca plc (ISIN GB0009895292 / WKN 886455) gab am Freitag eine Personalie bekannt.Den Angaben zufolge wird Rudy Markham mit sofortige. ...